Breakthroughs Surge as Weight-Loss Drug Development Enters a Period of Intensive Commercialization

　　【Pharmaceutical Network Industry DynamicsRecently, the global weight loss drug R&D field has received several pieces of good news. Among them, new drugs from Sciwind and Pfizer have been approved for marketing, while companies such as Hansoh Pharma have achieved phased R&D results.
 

On March 6, Sciwind announced that its self-developed cAMP-biased GLP-1 receptor agonist Ecnoglutide Injection (brand name: Sinovion®) has been officially approved for marketing by the National Medical Products Administration (NMPA). It is indicated for long-term weight management in adult patients with overweight/obesity, in conjunction with diet control and increased physical activity.
 

Ecnoglutide, a cAMP-biased long-acting GLP-1 receptor agonist independently developed by Sciwind, was approved on January 30 this year for glycemic control in adult patients with type 2 diabetes. On February 24, Sciwind announced a commercial strategic cooperation agreement with Pfizer. According to the agreement, Pfizer will obtain exclusive commercial rights to Ecnoglutide in mainland China, while Sciwind will be entitled to receive total payments of up to $495 million from Pfizer, including upfront payments, registration, and sales milestone payments.
 

It is reported that the Sciwind team is also making every effort to advance the research and development of the oral formulation (XW004), which has now entered Phase II clinical trials. The goal is to free patients from the trouble of injections and achieve the convenience of "one pill per week" treatment.
 

On the same day, Pfizer announced that the National Medical Products Administration (NMPA) had officially approved a new generation of cAMP-biased GLP-1 receptor agonist, Enotegruotide Injection (Xianweiying®), for long-term weight management in adult overweight/obesity patients based on dietary control and increased physical activity. Studies show that Enotegruotide, with its unique biased mechanism, breaks the longstanding clinical deadlock where 'efficacy' and 'patient tolerability' were difficult to balance, demonstrating steady weight loss and long-lasting stability.
 

In addition, Zealand Pharma, a Danish biotechnology company, also announced on March 6 the key data from the Phase 2 clinical trial Zupreme-1 of petrelintide, an amylin analog developed in collaboration with Roche for the treatment of obesity. This investigational drug, administered once weekly via injection, not only achieved an average weight loss of up to 10.7% over 42 weeks but also demonstrated tolerability comparable to that of a placebo.
 

On March 7, Hansoh Pharma announced that the glucagon-like peptide-1 receptor (GLP-1R)/glucose-dependent insulinotropic polypeptide receptor (GIPR) dual agonist, Oleblobotide (HS-20094), had achieved the primary endpoint in the first Phase III clinical trial (HS-20094-301) conducted in Chinese overweight or obese adult subjects.
 

Overall, the recent wave of new achievements in weight-loss drugs actually reflects the industry's transformation from "scale expansion" to "value cultivation." Industry insiders predict that 2026 will be a critical period for the concentrated market entry of Chinese-produced oral GLP-1 drugs, multi-target new drugs, and generic drugs, marking a golden phase where efficacy improves, prices drop, and accessibility significantly increases.
 

　　Disclaimer: In no event shall the information or opinions expressed in this article constitute investment advice to any person.